Moreover, the therapeutic potential of PKCγ inhibition has been hindered by the lack of an isoform specific inhibitor, but broad spectrum PKC inhibitors such as midostaurin have been shown to suppress tumorigenesis in AML and advanced systematic mastocytosis54. Here, PRRT2 is linked to acute myeloid leukemia.